Maternal anti-platelet β3 integrins impair angiogenesis and cause intracranial hemorrhage

Journal of Clinical Investigation

Volumn 125, Issue 4, 2015, Pages 1545-1556

  Yougbaré, Issaka ^a,b   Lang, Sean ^a,c   Yang, Hong ^a,b   Chen, Pingguo ^a,b   Zhao, Xu ^a,d   Tai, Wei She ^a   Zdravic, Darko ^a,b,c   Vadasz, Brian ^a,c   Li, Conglei ^a,c   Piran, Siavash ^a,c   Marshall, Alexandra ^a   Zhu, Guangheng ^a   Tiller, Heidi ^a,e   Killie, Mette Kjaer ^a,e   Boyd, Shelley ^a,d   Leong Poi, Howard ^a   Wen, Xiao Yan ^a,d   Skogen, Bjorn ^e   Adamson, S Lee ^d   Freedman, John ^a,c,d   Ni, Heyu ^a,b,c,d   more..

^a ST MICHAEL'S HOSPITAL   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BETA3 INTEGRIN; BETA3 INTEGRIN ANTIBODY; ENDOTHELIN 1; FIBROBLAST GROWTH FACTOR 1; IMMUNOGLOBULIN; MATERNAL ANTIBODY; NEUTROPHIL COLLAGENASE; PROTEIN KINASE B; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VITRONECTIN RECEPTOR; 1A ALLOANTIGEN, HUMAN; ADHESION RECEPTOR; AKT1 PROTEIN, HUMAN; ANTISERUM; AUTOANTIGEN; IMMUNOGLOBULIN G; ITGB3 PROTEIN, HUMAN; THROMBIN RECEPTOR; THROMBOCYTE ANTIGEN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIBODY TITER; APOPTOSIS; ARTICLE; BLOOD VESSEL PARAMETERS; BRAIN BLOOD VESSEL; BRAIN HEMORRHAGE; BRAIN VESSEL DENSITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; FETUS; FETUS DEVELOPMENT; FETUS ECHOGRAPHY; IN VIVO STUDY; NEONATAL ALLOIMMUNE THROMBOCYTOPENIA; NEUROPATHOLOGY; NEWBORN; NONHUMAN; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETINA BLOOD VESSEL; RETINA VESSEL DENSITY; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR SMOOTH MUSCLE; ANIMAL; ANTIBODY SPECIFICITY; BRAIN; DISEASE MODEL; EMBRYOLOGY; FETOMATERNAL TRANSFUSION; FETUS BLOOD; GENETICS; HUMAN; IMMUNOLOGY; INTRACRANIAL HEMORRHAGES; KNOCKOUT MOUSE; MALE; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; PASSIVE IMMUNIZATION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; THROMBOCYTE; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULARIZATION;

ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, HUMAN PLATELET; APOPTOSIS; AUTOANTIGENS; BLOOD PLATELETS; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; FETAL BLOOD; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNE SERA; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; INTEGRIN BETA3; INTRACRANIAL HEMORRHAGES; MALE; MATERNAL-FETAL EXCHANGE; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PREGNANCY; PROTO-ONCOGENE PROTEINS C-AKT; RETINAL VESSELS; THROMBOCYTOPENIA, NEONATAL ALLOIMMUNE;

EID: 84926312039     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI77820     Document Type: Article

References (69)

1. Bussel JB, Primiani A. Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates. Blood Rev. 2008;22(1):33-52.
2. Chen P, et al. Animal model of fetal and neonatal immune thrombocytopenia: role of neonatal Fc receptor in the pathogenesis and therapy. Blood. 2010;116(18):3660-3668.
3. Bertrand G, Drame M, Martageix C, Kaplan C. Prediction of the fetal status in noninvasive management of alloimmune thrombocytopenia. Blood. 2011;117(11):3209-3213.
4. Mueller-Eckhardt C, et al. 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet. 1989;1(8634):363-366.
5. Kjeldsen-Kragh J, et al. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. Blood. 2007;110(3):833-839.
6. Curtis BR, McFarland JG. Human platelet antigens - 2013. Vox Sang. 2014;106(2):93-102.
7. Kuijpers RW, Ouwehand WH, Bleeker PM, Christie D, von dem Borne AE. Localization of the platelet-specific HPA-2 (Ko) alloantigens on the N-terminal globular fragment of platelet glycoprotein Ib alpha. Blood. 1992;79(1):283-288.
8. Silva F, Morais S, Sevivas T, Veiga R, Salvado R, Taborda A. Severe intracranial haemorrhage in neonatal alloimmune thrombocytopenia. BMJ Case Rep. 2011;2011:bcr0720114563.
9. Tiller H, et al. Fetal intracranial haemorrhages caused by fetal and neonatal alloimmune thrombocytopenia: an observational cohort study of 43 cases from an international multicentre registry. BMJ Open. 2013;3(3):e002490.
10. Cota F, et al. A severe case of intracranial hemorrhage due to alloimmune thrombocytopenia. J Matern Fetal Neonatal Med. 2008;21(11):852-854.
11. Shivdasani RA, et al. Transcription factor NF-E2 is required for platelet formation independent of the actions of thrombopoietin/MGDF in megakaryocyte development. Cell. 1995;81(5):695-704.
12. Goerge T, et al. Inflammation induces hemorrhage in thrombocytopenia. Blood. 2008;111(10):4958-4964.
13. Webster ML, et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood. 2006;108(3):943-946.
14. Suh TT, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogendeficient mice. Genes Dev. 1995;9(16):2020-2033.
15. Yang H, et al. Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. J Thromb Haemost. 2006;4(10):2230-2237.
16. Reheman A, et al. Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor. Blood. 2009;113(8):1809-1817.
17. Palumbo JS, Zogg M, Talmage KE, Degen JL, Weiler H, Isermann BH. Role of fibrinogen-and platelet-mediated hemostasis in mouse embryogenesis and reproduction. J Thromb Haemost. 2004;2(8):1368-1379.
18. Nichol D, et al. Impaired angiogenesis and altered Notch signaling in mice overexpressing endothelial Egfl7. Blood. 2010;116(26):6133-6143.
19. Takakura N, et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell. 2000;102(2):199-209.
20. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol. 2004;24(6):1015-1022.
21. Carmeliet P, et al. Role of tissue factor in embryonic blood vessel development. Nature. 1996;383(6595):73-75.
22. Greenberg DA, Jin K. From angiogenesis to neuropathology. Nature. 2005;438(7070):954-959.
23. Liu J, et al. A betaPix Pak2a signaling pathway regulates cerebral vascular stability in zebrafish. Proc Natl Acad Sci U S A. 2007;104(35):13990-13995.
24. Ballabh P, et al. Angiogenic inhibition reduces germinal matrix hemorrhage. Nat Med. 2007;13(4):477-485.
25. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994;264(5158):569-571.
26. Brooks PC, et al. Integrin avβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994;79(7):1157-1164.
27. Di Q, et al. Impaired cross-activation of β3 integrin and VEGFR-2 on endothelial progenitor cells with aging decreases angiogenesis in response to hypoxia. Int J Cardiol. 2013;168(3):2167-2176.
28. Stupack DG, Cheresh DA. Integrins and angiogenesis. Curr Top Dev Biol. 2004;64:207-238.
29. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med. 2002;8(9):918-921.
30. Reynolds LE, et al. Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins. Nat Med. 2002;8(1):27-34.
31. Robinson SD, et al. avβ3 Integrin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis. J Biol Chem. 2009;284(49):33966-33981.
32. Soldi R, Mitola S, Strasly M, Defilippi P, Tarone G, Bussolino F. Role of avβ3 integrin in the activation of vascular endothelial growth factor receptor-2 EMBO J. 1999;18(4):882-892.
33. Kitamura T, et al. Regulation of VEGF-mediated angiogenesis by the Akt/PKB substrate Girdin. Nat Cell Biol. 2008;10(3):329-337.
34. Bader BL, Rayburn H, Crowley D, Hynes RO. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell. 1998;95(4):507-519.
35. McCarty JH, et al. Selective ablation of alphav integrins in the central nervous system leads to cerebral hemorrhage, seizures, axonal degeneration and premature death. Development. 2005;132(1):165-176.
36. Jacobson EM, et al. A CD40 Kozak sequence polymorphism and susceptibility to antibodymediated autoimmune conditions: the role of CD40 tissue-specific expression. Genes Immun. 2007;8(3):205-214.
37. Li C, et al. The maternal immune response to fetal platelet GPIba causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. J Clin Invest. 2011;121(11):4537-4547.
38. Abboud N, et al. Human platelet alloantigens HPA-1, HPA-2, and HPA-3 polymorphisms associated with extent of severe coronary artery disease. J Thromb Thrombolysis. 2010;29(4):409-415.
39. Uotila J, Tammela O, Makipernaa A. Fetomaternal platelet immunization associated with maternal Bernard-Soulier syndrome. Am J Perinatol. 2008;25(4):219-223.
40. Ni H, et al. A novel murine model of fetal and neonatal alloimmune thrombocytopenia: response to intravenous IgG therapy. Blood. 2006;107(7):2976-2983.
41. Nieswandt B, Bergmeier W, Rackebrandt K, Gessner JE, Zirngibl H. Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood. 2000;96(7):2520-2527.
42. Nieswandt B, et al. Targeting of platelet integrin aIIbβ3 determines systemic reaction and bleeding in murine thrombocytopenia regulated by activating and inhibitory FcR. Int Immunol. 2003;15(3):341-349.
43. Scheppke L, et al. Notch promotes vascular maturation by inducing integrin-mediated smooth muscle cell adhesion to the endothelial basement membrane. Blood. 2012;119(9):2149-2158.
44. Ren B, et al. ERK1/2-Akt1 crosstalk regulates arteriogenesis in mice and zebrafish. J Clin Invest. 2010;120(4):1217-1228.
45. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008;359(9):938-949.
46. Ruggeri ZM. Platelets in atherothrombosis. Nat Med. 2002;8(11):1227-1234.
47. Frenette PS, Wagner DD. Adhesion molecules - Part II: Blood vessels and blood cells. N Engl J Med. 1996;335(1):43-45.
48. Wang Y, et al. Platelets in thrombosis and hemostasis: old topic with new mechanisms. Cardiovasc Hematol Disord Drug Targets. 2012;12(2):126-132.
49. Ni H, Freedman J. Platelets in hemostasis and thrombosis: role of integrins and their ligands. Transfus Apher Sci. 2003;28(3):257-264.
50. Roberts HR, Hoffman M, Monroe DM. A cellbased model of thrombin generation. Semin Thromb Hemost. 2006;32(suppl 1):32-38.
51. Kaplan C. Foetal and neonatal alloimmune thrombocytopaenia. Orphanet J Rare Dis. 2006;1:39.
52. Bussel JB, et al. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol. 2010;203(2):135 e131-135 e114.
53. Ziai WC, Torbey MT, Kickler TS, Oh S, Bhardwaj A, Wityk RJ. Platelet count and function in spontaneous intracerebral hemorrhage. J Stroke Cerebrovasc Dis. 2003;12(4):201-206.
54. Schmaier AH. Are maternal antiplatelet antibodies a prothrombotic condition leading to miscarriage? J Clin Invest. 2011;121(11):4241-4243
55. Chen J, et al. Wnt signaling mediates pathological vascular growth in proliferative retinopathy. Circulation. 2011;124(17):1871-1881.
56. Friedlander M, et al. Involvement of integrins avβ3 and avβ5 in ocular neovascular diseases. Proc Natl Acad Sci U S A. 1996;93(18):9764-9769.
57. Ward MJ, Pauliny J, Lipper EG, Bussel JB. Long-term effects of fetal and neonatal alloimmune thrombocytopenia and its antenatal treatment on the medical and developmental outcomes of affected children. Am J Perinatol. 2006;23(8):487-492.
58. Hodivala-Dilke KM, et al. β3-Integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999;103(2):229-238.
59. Kabir-Salmani M, et al. avβ3 Integrin signaling pathway is involved in insulin-like growth factor I-stimulated human extravillous trophoblast cell migration. Endocrinology. 2003;144(4):1620-1630.
60. Tiller H, et al. Platelet antibodies and fetal growth: maternal antibodies against fetal platelet antigen 1a are strongly associated with reduced birthweight in boys. Acta Obstet Gynecol Scand. 2012;91(1):79-86.
61. Tiller H, et al. Toward a prophylaxis against fetal and neonatal alloimmune thrombocytopenia: induction of antibody-mediated immune suppression and prevention of severe clinical complications in a murine model. Transfusion. 2012;52(7):1446-1457.
62. Kiefel V, et al. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT). Blood. 2006;107(9):3761-3763.
63. Li C, et al. Co-stimulation with LPS or Poly I:C markedly enhances the anti-platelet immune response and severity of fetal and neonatal alloimmune thrombocytopenia. Thromb Haemost. 2013;110(6):1250-1258.
64. Ni H, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest. 2000;106(3):385-392.
65. Reheman A, et al. Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost. 2005;3(5):875-883.
66. Lei X, et al. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost. 2014;111(2):279-289.
67. Foster FS, Hossack J, Adamson SL. Micro-ultrasound for preclinical imaging. Interface Focus. 2011;1(4):576-601.
68. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody - specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. Blood. 1987;70(6):1722-1726.
69. Li J, Callum JL, Lin Y, Zhou Y, Zhu G, Ni H. Severe platelet desialylation in a patient with glycoprotein Ib/IX antibody-mediated immune thrombocytopenia and fatal pulmonary hemorrhage. Haematologica. 2014;99(4):e61-e63.